Compile Data Set for Download or QSAR
maximum 50k data
Found 380 with Last Name = 'barilli' and Initial = 'a'
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Chiesi Farmaceutici

US Patent
LigandPNGBDBM645506(4-{[6-(5-chloro-2-fluorophen- yl)pyridazin-4-yl]am...)
Affinity DataIC50: <1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Chiesi Farmaceutici

US Patent
LigandPNGBDBM645507(2-(morpholin-4-yl)ethyl 4-{[6- (5-chloro-2-fluorop...)
Affinity DataIC50: <1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Chiesi Farmaceutici

US Patent
LigandPNGBDBM645560(US20240018122, Example 171 | methyl 4-{[6-(5-chlor...)
Affinity DataIC50: <1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Chiesi Farmaceutici

US Patent
LigandPNGBDBM645561(US20240018122, Example 177 | [6-(5-chloro-2-fluoro...)
Affinity DataIC50: <1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Chiesi Farmaceutici

US Patent
LigandPNGBDBM645562(N-[6-(5-chloro-2-fluorophenyl)- 3-(trifluoromethyl...)
Affinity DataIC50: <1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Chiesi Farmaceutici

US Patent
LigandPNGBDBM645563(4-{[6-(5-chloro-2-fluoro- phenyl)pyridazin-4-yl]- ...)
Affinity DataIC50: <1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Chiesi Farmaceutici

US Patent
LigandPNGBDBM645564(4-{[6-(5-chloro-2-fluoro- phenyl)pyridazin-4-yl]- ...)
Affinity DataIC50: <1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Chiesi Farmaceutici

US Patent
LigandPNGBDBM645565(4-{[6-(5-chloro-2-fluoro- phenyl)pyridazin-4-yl]- ...)
Affinity DataIC50: <1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Chiesi Farmaceutici

US Patent
LigandPNGBDBM645566(4-{[6-(5-chloro-2-fluoro- phenyl)-3-methylpyrid- a...)
Affinity DataIC50: <1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Chiesi Farmaceutici

US Patent
LigandPNGBDBM645567(4-{[6-(5-chloro-2-fluoro- phenyl)-3-methylpyrid- a...)
Affinity DataIC50: <1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Chiesi Farmaceutici

US Patent
LigandPNGBDBM645450(N-(4-{[6-(5-chloro-2- fluorophenyl)-3- methylpyrid...)
Affinity DataIC50: <1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Chiesi Farmaceutici

US Patent
LigandPNGBDBM645446(N-(4-{[6-(5-chloro-2- fluorophenyl)-3- methylpyrid...)
Affinity DataIC50: <1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Chiesi Farmaceutici

US Patent
LigandPNGBDBM645452(US20240018122, Example 122 | ethyl 4-{2-[(4-{[6-(5...)
Affinity DataIC50: <1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Chiesi Farmaceutici

US Patent
LigandPNGBDBM645453(4-{[(4-{[6-(5-chloro-2- fluorophenyl)-3- methylpyr...)
Affinity DataIC50: <1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Chiesi Farmaceutici

US Patent
LigandPNGBDBM645454(N-(4-{[6-(5-chloro-2- fluorophenyl)-3- methylpyrid...)
Affinity DataIC50: <1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Chiesi Farmaceutici

US Patent
LigandPNGBDBM645455(US20240018122, Example 126 | propan-2-yl 4-{2-[(4-...)
Affinity DataIC50: <1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Chiesi Farmaceutici

US Patent
LigandPNGBDBM645456(US20240018122, Example 127 | cyclopropyl 4-{2-[(4-...)
Affinity DataIC50: <1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Chiesi Farmaceutici

US Patent
LigandPNGBDBM645457(US20240018122, Example 129 | oxetan-3-yl 4-{2-[(4-...)
Affinity DataIC50: <1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Chiesi Farmaceutici

US Patent
LigandPNGBDBM645458(N-(4-{[6-(5-chloro-2- fluorophenyl)-3- methylpyrid...)
Affinity DataIC50: <1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Chiesi Farmaceutici

US Patent
LigandPNGBDBM645459(N-(4-{[6-(5-chloro-2- fluorophenyl)-3- methylpyrid...)
Affinity DataIC50: <1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Chiesi Farmaceutici

US Patent
LigandPNGBDBM645460(N-(4-{[6-(5-chloro-2- fluorophenyl)-3- methylpyrid...)
Affinity DataIC50: <1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Chiesi Farmaceutici

US Patent
LigandPNGBDBM645461(N-(4-{[6-(5-chloro-2- fluorophenyl)-3- methylpyrid...)
Affinity DataIC50: <1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Chiesi Farmaceutici

US Patent
LigandPNGBDBM645462(N-(4-{[6-(5-chloro-2- fluorophenyl)-3- methylpyrid...)
Affinity DataIC50: <1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Chiesi Farmaceutici

US Patent
LigandPNGBDBM645463(N-(4-{[6-(5-chloro-2- fluorophenyl)-3- methylpyrid...)
Affinity DataIC50: <1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Chiesi Farmaceutici

US Patent
LigandPNGBDBM645464(N-(4-{[6-(5-chloro-2- fluorophenyl)-3- methylpyrid...)
Affinity DataIC50: <1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Chiesi Farmaceutici

US Patent
LigandPNGBDBM645465(N-(4-{[6-(5-chloro-2- fluorophenyl)-3- methylpyrid...)
Affinity DataIC50: <1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Chiesi Farmaceutici

US Patent
LigandPNGBDBM645466(1-(4-{[6-(5-chloro-2- fluorophenyl)-3- methylpyrid...)
Affinity DataIC50: <1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Chiesi Farmaceutici

US Patent
LigandPNGBDBM645467(1-(4-((6-(5-chloro-2- fluorophenyl)-3- methylpyrid...)
Affinity DataIC50: <1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Chiesi Farmaceutici

US Patent
LigandPNGBDBM645468(N-(4-{[6-(5-chloro-2- fluorophenyl)-3- methylpyrid...)
Affinity DataIC50: <1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Chiesi Farmaceutici

US Patent
LigandPNGBDBM645469(N-(4-{[6-(5-chloro-2- fluorophenyl)-3- methylpyrid...)
Affinity DataIC50: <1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Chiesi Farmaceutici

US Patent
LigandPNGBDBM645470(N-(4-{[6-(5-chloro-2- fluorophenyl)-3- methylpyrid...)
Affinity DataIC50: <1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Chiesi Farmaceutici

US Patent
LigandPNGBDBM645471(N-(4-{[6-(5-chloro-2- fluorophenyl)-3- methylpyrid...)
Affinity DataIC50: <1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Chiesi Farmaceutici

US Patent
LigandPNGBDBM645472(N-(4-{[6-(5-chloro-2- fluorophenyl)-3- methylpyrid...)
Affinity DataIC50: <1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Chiesi Farmaceutici

US Patent
LigandPNGBDBM645473(N-(4-{[6-(5-chloro-2- fluorophenyl)-3- methylpyrid...)
Affinity DataIC50: <1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Chiesi Farmaceutici

US Patent
LigandPNGBDBM645474(N-(4-{[6-(5-chloro-2- fluorophenyl)-3- methylpyrid...)
Affinity DataIC50: <1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Chiesi Farmaceutici

US Patent
LigandPNGBDBM645475(N-(4-{[6-(5-chloro-2,4- difluorophenyl)-3- methylp...)
Affinity DataIC50: <1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Chiesi Farmaceutici

US Patent
LigandPNGBDBM645476(N-(4-{[6-(5-chloro-2- fluorophenyl)-3- methylpyrid...)
Affinity DataIC50: <1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Chiesi Farmaceutici

US Patent
LigandPNGBDBM645477(N-(4-{[6-(5-chloro-2- fluorophenyl)-3- methylpyrid...)
Affinity DataIC50: <1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Chiesi Farmaceutici

US Patent
LigandPNGBDBM645478(N-(4-{[6-(5-chloro-2- fluorophenyl)-3- methylpyrid...)
Affinity DataIC50: <1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Chiesi Farmaceutici

US Patent
LigandPNGBDBM645479(N-(4-{[6-(5-chloro-2- fluorophenyl)-3- methylpyrid...)
Affinity DataIC50: <1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Chiesi Farmaceutici

US Patent
LigandPNGBDBM645480(N-(4-{[6-(5-chloro-2- fluorophenyl)-3- methylpyrid...)
Affinity DataIC50: <1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Chiesi Farmaceutici

US Patent
LigandPNGBDBM645481(N-(4-{[6-(5-chloro-2- fluorophenyl)-3- methylpyrid...)
Affinity DataIC50: <1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Chiesi Farmaceutici

US Patent
LigandPNGBDBM645482(US20240018122, Example 162 | cis N-(4-{[6-(5-chlor...)
Affinity DataIC50: <1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Chiesi Farmaceutici

US Patent
LigandPNGBDBM645483(N-(4-{[6-(5-chloro-2- fluorophenyl)-3- methylpyrid...)
Affinity DataIC50: <1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Chiesi Farmaceutici

US Patent
LigandPNGBDBM645484(N-(4-{[6-(5-chloro-2- fluorophenyl)-3- methylpyrid...)
Affinity DataIC50: <1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Chiesi Farmaceutici

US Patent
LigandPNGBDBM645485(N-(4-{[6-(5-chloro-2- fluorophenyl)-3- methylpyrid...)
Affinity DataIC50: <1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Chiesi Farmaceutici

US Patent
LigandPNGBDBM645486(N-4-[6-(5-chloro-2- fluorophenyl)-3- methylpyridaz...)
Affinity DataIC50: <1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Chiesi Farmaceutici

US Patent
LigandPNGBDBM645487(N-(4-{[6-(5-chloro-2- fluorophenyl)-3- methylpyrid...)
Affinity DataIC50: <1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Chiesi Farmaceutici

US Patent
LigandPNGBDBM645488(N-(4-{[6-(5-chloro-2- fluorophenyl)-3- methylpyrid...)
Affinity DataIC50: <1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Chiesi Farmaceutici

US Patent
LigandPNGBDBM645489(N-(4-{[6-(5-chloro-2- fluorophenyl)-3- cyclopropyl...)
Affinity DataIC50: <1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Displayed 1 to 50 (of 380 total ) | Next | Last >>
Jump to: